Development and validation of a sensitive and accurate method for determination of atorvastatin and rosuvastatin in rat plasma by reversed- phase high performance liquid chromatography with UV detection

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue SUPPL. 2, 2013, Pages 211-219

  Al Akkam, Entidhar J ^a   Abdul Rasool, Alaa A ^a   Badwan, Adnan A ^b   Al Jbour, Nawzat D ^b   Qinna, Nidal A ^c  

^a UNIVERSITY OF BAGHDAD   (Iraq)

^b JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

^c UNIVERSITY OF PETRA   (Jordan)

Author keywords

Atorvastatin; Plasma; Rosuvastatin; RP HPLC and validation; Statin

Indexed keywords

ATORVASTATIN; DICLOFENAC; NAPROXEN; ROSUVASTATIN;

ACCURACY; ARTICLE; CONCENTRATION (PARAMETERS); DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NONHUMAN; RAT; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 84878405683     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Merck index, an encyclopedia of chemicals, drugs, and biological. 4th ed., Maryadele J.O. Neil, Editor, Merck & Co. INC, USA (2006), p 864-865.
2. Remington. The science and practice of pharmacy 21th ed., Lippincott Williams and Wilkins (2006), p1369.
3. Law M. R., Wald N. J., Rudnicka A. R., Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med.J. 2003; 326: 1423-1429.
4. Juan T., Ricardo C., Ricardo G., Lucía N., Miguel V., Eva D., Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy, J. Pharmacology & Therapeutics. 2007; 114: 107-126.
5. Lei Z., Shuning Z., Hong J., Aijun S., Yunzeng Z., Junbo G., Effects of Statin Treatment on Cardiac Function in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Cardiol. 2011; 34, 2: 117-123.
6. Lennernas H., Clinical pharmacokinetics of atorvastatin. J. Clin. Pharmacokinet. 2003; 42: 1141-1160.
7. Lippincott's IIIustrated Reviews Pharmacology, 4th ed., Lippincott Williams and Wilkins (2009), p253-254.
8. Pasquale M., Giustina V., Aurelio S., Francesco P., Ilenia P., Carmelna R., Salvatore D., Giovam B., Enrico C., Mevalonate pathway: Role of biphoslphonates and statins. J. Acta Medica Mediterranea. 2011; 27: 85-95.
9. Srinivasa R., Prasad T., Mohanta G. P., Manna P. K., An Overview of Statins as Hypolipidemic Drugs. International Journal of Pharmaceutical Sciences and Drug Research. 2011; 3: 178-183.
10. Ebru D.S., Eser Y.S., Deniz N., Taner 0., Effect of atorvastatin therapy on oxidant-antioxidant status andatherosclerotic plaque formation. J. Vascular Health and Risk Management. 2011; 7: 333-343.
11. Preston M., Mary F. W., Charles A. D., Robert F. J., Active Metabolite of Atorvastatin Inhibits Membrane Cholesterol Domain Formation by an Antioxidant Mechanism. Journal of Biological Chemistry. 2006; 281: 9337-9345.
12. Carmen C., Bucharest, Romania, The statins as anticancer agents. Maedica-a Journal of Clinical Medicine. 2012; 7: 337.
13. Sune F. N., Borge G. N., Stig E. B., Statin Use and Reduced Cancer Related Mortality. The New England Journal of Medicine. 2012; 367: 1792-1802.
14. Anuradha G., Nancy C., Jeanette H., Jing Q., Catherine R., Julia M., Carolyn B., Jean V., Catherine F. D., Peter S., Mary B., Sybil T., Dean F., Frank M., High Dose Atorvastatin Decreases Cellular Markers of Immune Activation without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial. The Journal of Infectious Diseases. 2011; 203:756-764.
15. Aryeh M., Abeles, Michael H., Pillinger, Statins as anti-inflammatory and immunomodulatory Agents. J. Arithritis & Rhumatism. 2006; 54: 393-407.
16. Ulrike R., Franz T., Alexandra B., Helmut S., Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol.2005; 61(3): 262-274.
17. Rina P. M., Wong and Timothy M. E., Davis, Statins as Potential Antimalarial Drugs: Low Relative Potency and Lack of Synergy with Conventional Antimalarial Drugs. J. American Society for Microbiology. 2009; 53(5): 2212-2214.
18. Veronique P., Maud H., Nathalie W., Jerome D., Sebastien B., Marine G., Eric B., Remy A., Christophe R., Bruno P., Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Malaria Journal. 2010; 9: 139-145.
19. László G., Ildikó N., Tamás P., Csaba V., Statins as antifungal agents. World J Clin Infect Dis. 2011; 1(1): 4-10.
20. Bernard U., Régis C., Patrick N., Michel C., Gérard-Yves P., Effects of statins on bone mineral density: A meta-analysis of clinical studies. J. Bone. 2007; 40: 1581-1587.
21. Athanasios N. T., Charalambos D., Georgia D. K., Dimitris N. T., Antonios K., Apostolos I. H., Christos G. S., Statins, bone formation and osteoporosis: hope or hype? J. Hormones. 2012; 11(2): 126-139.
22. Peter J., Stephanie K., Irene L., Donald H., Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The Curves Study). The American Journal of Cardiology. 1998; 81: 582-587.
23. Peter H. J., Michael H. D., Evan A. S., Harold E. B., James M. M., Elinor M., Valerie A. C., James W. B., Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses. The American Journal of Cardiology. 2003; 93: 152-160.
24. Michael B. C., John A., Jean-Pierre B., Hugo R., Hernández G., Sam S. M., Froukje F. S., Michael K. P., Brian S. B., Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia-Prospective study to evaluate the Use of Low doses of the StatinsAtorvastatin and Rosuvastatin. J. Trials. 2006; 7:35
25. Keijiro S., Bo Z., Keita N., Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL). Circulation Journal. 2011; 10: 1281.
26. Joyce S. M., Ileana A. I., Miroslav D., Fatemeh A., Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS). J. Anal Bioanal Chem. 2011; 400(2): 423-433.
27. Ashutosh J. J., Bhavesh D., Shivprakash R., Anita A. M., Liquid Chromatographic-MS/ MS Determination of Atorvastatin and Metabolites in Human Plasma. Eurasian J. Anal. Chem. 2010; 5(1): 46-52.
28. Gholamreza B., Bahareh M., Shahla M., Amir K., Determination of atorvastatin in human serum by reversedphase high-performance liquid chromatography with UV detection. J. Chromatography B. 2005; 826: 41-45.
29. Hadi F., Parviz N., Abolghasem B., Hamid R. S., Rasoul D., Mohammad R. G., Quantitation of atorvastatin in human plasma using directly suspended acceptor droplet in liquid-liquid-liquid microextraction and high-performance liquid chromatography-ultraviolet detection. J. Talanta. 2009; 80: 1001-1006.
30. Gulam M., Adnan A., Farhan J. A., Zeenat I. K., Faiyaz S., Sushma T., Stability-Indicating RP-HPLC Method for Analysis of Atorvastatin in Bulk Drug, Marketed Tablet and Nanoemulsion Formulation. J. Chil. Chem. Soc. 2010; 55(2): 184-188.
31. Beata S., Lukasz K., Validation of HPLC Method for Determination of Atorvastatin in Tablets and for Monitoring Stability in Solid Dosage Form. J. Acta Poloniac Pharmaceutica-Drug Research. 2006; 63(6): 471-476.
32. Moynul H., Zebunnesa A., Ruhul A., Neher S. S., Development and Validation of a Spectrophotometric Method for Determination of Atorvastatin Calcium in Bulk Drug and Pharmaceutical Formulation. International Journal of Pharma Research and Development (IJPRD). 2011; 2:116-121.
33. Manzoor A., Manohara Y.N., Ravi M.C., RP-HPLC method development and validation for simultaneous estimation of Atorvastatin calcium and Amlodipine besylate. International Journal of ChemTech Research. 2012; 4(1): 337-345.
34. Suresh R., Manavalan R., and Valliappan K., Developing and optimizing a validated RP-HPLC method for the analysis of amlodipine and ezetimibe with atorvastatin in pharmaceutical dosage forms applying response surface methodology. Int J Pharm Pharm Sci. 2012; 4(3): 550-558.
35. Jaiprakash N. S., Zahid Z., Mohammed A., Validated Spectrophotometric Method for Simultaneous Estimation of Atorvastatin and Nicotinic acid in Combined Pharmaceutical dosage form. International Journal of PharmTech Research. 2012; 4(3): 999-1003.
36. Suma B. V., Kannan K., Madhavan V., Chandini R. N., Simultaneous Estimation and Validation of Atorvastatin Calcium and Aspirin in Combined Capsule Dosage Form by RP HPLC Method. Journal of Chemistry. 2012; 9(3):1449-1456.
37. Nikitan N. P., Parag R. P., Falguni A. T., Charmy S. K., Shailesh A. S., Ratio derivative spectrophotometric method for simultaneous estimation of olmesartan medoxomil and atorvastatin calicium in their combined tablet dosage form. Int J Pharm Pharm Sci. 2012; 4(Suppl 5): 222-226.
38. Kumar P., Ghosh A., Chaudhary M., Stability Indicating Method Development for Simultaneous Estimation of Ezetimibe and Atorvastatin in Pharmaceutical Formulations by RP-HPLC. J. Pharmaceutica Analytica Acta. 2012; 3:164-169.
39. Jayapal R. S., Rama R. K., Surya N. R., Reddanna p., Simultaneous Estimation of Atorvastatin and Ezetimibe in Pharmaceutical Formulation by RP-HPLC Method. J. Der Pharmacia Lettre. 2010; 2(1): 427-436.
40. Fazli N., Zafar I., Abad K., Lateef A., Yasar S., Amir Z. K., Jamshaid A. K., Salimullah K., Simultaneous determination of timolol maleate, rosuvastatin calcium and diclofenac sodium in pharmaceuticals and physiological fluids using HPLC-UV. Journal of Chromatography B. 2011; 879: 3434-3443.
41. Dujuan Z., Jing Z., Xiaoyan L., Chunmin W., Rui Z., Haojing S., Han., Guiyan., Benjie W., Ruichen G., Validated LC-MS/MS Method for the Determination of Rosuvastatin in Human Plasma: Application to a Bioequivalence Study in Chinese Volunteers. J. Pharmacology & Pharmacy. 2011; 2: 341-346.
42. Anuradha K. G., Vishal D. S., Development and Validation of a Stability-Indicating Reversed-Phase HPLC Method for Simultaneous Estimation of Rosuvastatin and Ezetimibe from Their Combination Dosage Forms. Eurasian J. Anal. Chem. 2010; 5(3): 280-298.
43. Ashwini J. P., Balap AR., Jadhav SB., Chaudhari PD., Development and Validation of UV Spectrophotometric Method for Simultaneous Determination of Rosuvastatin Calcium and Aspirin in its Pure and Pharmaceutical Dosage Forms. International Journal of Pharmaceutical and Chemical Sciences. 2012; 1(3): 659-663.
44. Shivva V., Nikhil R.S., Thammera R. K., Menon C. A., Ramesh M., Nuggehally R. S., Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. J. Biomedical Chromatography. 2006; 20: 1252-1259.
45. Mohd M., Rahaman S.A., Ramakrishna Y. B., Ramakrishna B., Development and validation of a reverse phase HPLC method for simultaneous estimation of rosuvastatin calcium and fenofibrate in tablet dosage form. Int J Pharm Pharm Sci. 2012; 4 (Suppl 3): 150-154
46. Najma S., Saeed A., Shabana N. S., Nighat S., Safila N., Simultaneous Determination of Prazosin, Atorvastatin, Rosuvastatin and Simvastatin in API, Dosage Formulations and Human Serum by RP-HPLC. Journal of the Chinese Chemical Society.2010; 57: 1286-1292.
47. Yasar S., Zafar I., Lateef A., Abad K., Muhammad I.K., Shabnam N., Fazli N., Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: Method development, validation and optimization of various experimental parameters. Journal of Chromatography B. 2011; 879: 557-563.
48. Epshtein N. A., Validation of HPLC techniques for pharmaceutical analysis. Pharm. Chem. J. 2004; 38: 212-228.
49. Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). May (2001), p 1-22.